Literature DB >> 23265741

Phenotype in patients with Gaucher disease and Parkinson disease.

Eli Ben Chetrit1, Roy N Alcalay, Bettina Steiner-Birmanns, Gheona Altarescu, Mici Phillips, Deborah Elstein, Ari Zimran.   

Abstract

BACKGROUND: Previous reports have shown an increased risk for Parkinson disease (PD) among type 1 Gaucher disease (GD) patients. However, the number of the reported cases of GD/PD is small and it is unknown whether certain GD phenotypes are associated with an increased PD risk.
OBJECTIVE: To present GD and PD characteristics of adults affected by both diseases from a large Israeli GD clinic, and assess whether certain GD characteristics are associated with a higher risk for PD.
METHODS: Medical files of patients >18years between 1990 and 2010 were reviewed for PD signs or symptoms. Available patients with PD underwent an additional neurological examination. Demographic and GD characteristics were compared between GD patients with and without PD using t-test and Fisher exact. Kaplan-Meier survival curves were used to estimate age-specific risk for PD among males and females. Age-specific risk for PD was compared between males and females using Cox Hazard ratio model.
RESULTS: 510 type 1 GD adults (233 males; 45.7%), were evaluated. 11 PD patients were identified (2.2%). Among those with GD/PD cognitive impairment was common (7/11). Two patients underwent successful deep brain stimulation (DBS). PD diagnosis was associated with male gender (81.8% versus 44.9% male, p=0.027) and older age (mean age, PD=62.8, non-PD=47.1, p=0.004). GD phenotype and severity did not differ between the two groups, including mean Zimran Severity Score index (7.7 versus 8.3), percent splenectomized (15.8% versus 27.3%), history of avascular necrosis (13.0% versus 27.3%) and percent ever treated with enzyme replacement (49.4% versus 45.5%).
CONCLUSION: Male gender and older age are risk factors for PD among GD patients, but GD severity is not associated with increased risk for PD. Further research is required to assess which GD patients are at a higher risk for PD, and why.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23265741     DOI: 10.1016/j.bcmd.2012.11.011

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  14 in total

Review 1.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

2.  Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Authors:  Matthew Swan; Nancy Doan; Robert A Ortega; Matthew Barrett; William Nichols; Laurie Ozelius; Jeannie Soto-Valencia; Sarah Boschung; Andres Deik; Harini Sarva; Jose Cabassa; Brooke Johannes; Deborah Raymond; Karen Marder; Nir Giladi; Joan Miravite; William Severt; Rivka Sachdev; Vicki Shanker; Susan Bressman; Rachel Saunders-Pullman
Journal:  J Neurol Sci       Date:  2016-08-30       Impact factor: 3.181

3.  Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.

Authors:  Roy N Alcalay; Tama Dinur; Timothy Quinn; Karina Sakanaka; Oren Levy; Cheryl Waters; Stanley Fahn; Tsvyatko Dorovski; Wendy K Chung; Michael Pauciulo; William Nichols; Huma Q Rana; Manisha Balwani; Louise Bier; Deborah Elstein; Ari Zimran
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

Review 4.  The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.

Authors:  Elma Aflaki; Wendy Westbroek; Ellen Sidransky
Journal:  Neuron       Date:  2017-02-22       Impact factor: 17.173

Review 5.  Skin Conditions and Movement Disorders: Hiding in Plain Sight.

Authors:  Kristina Kulcsarova; Janette Baloghova; Jan Necpal; Matej Skorvanek
Journal:  Mov Disord Clin Pract       Date:  2022-03-24

6.  Glucocerebrosidase and parkinsonism: lessons to learn.

Authors:  Ivanka Marković; Nikola Kresojević; Vladimir S Kostić
Journal:  J Neurol       Date:  2016-03-19       Impact factor: 4.849

Review 7.  Enzyme replacement and substrate reduction therapy for Gaucher disease.

Authors:  Elad Shemesh; Laura Deroma; Bruno Bembi; Patrick Deegan; Carla Hollak; Neal J Weinreb; Timothy M Cox
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

8.  The Successful Three-Year Outcome of Deep Brain Stimulation in Gaucher Disease Type 1 Associated Parkinson's Disease: A Case Report.

Authors:  Valentino Racki; Elisa Papic; Fadi Almahariq; Darko Chudy; Vladimira Vuletic
Journal:  Mov Disord Clin Pract       Date:  2021-03-23

9.  Parkinson disease in Gaucher disease.

Authors:  Federico Rodriguez-Porcel; Alberto J Espay; Miryam Carecchio
Journal:  J Clin Mov Disord       Date:  2017-05-23

Review 10.  Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features.

Authors:  Nattakarn Limphaibool; Piotr Iwanowski; Marte Johanne Veilemand Holstad; Katarzyna Perkowska
Journal:  Front Neurol       Date:  2018-10-12       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.